Pfizer Gets Phase III Results, Acquires InnoPharma

Last week Pfizer announced that their hemophilia B factor medication, BeneFix, reduced the annual bleeding rate during once weekly prophylaxis regimens than with on-demand treatment according to PharmaTimes.

“This data adds to the growing body of clinical evidence showing that prophylaxis treatment has the potential to reduce the number of bleeds in a year, the most critical factor in hemophilia management,” says Steven Romano, medicines development head for global innovative pharmaceuticals at Pfizer.

Pfizer also recently bought InnoPharma for about $360 million last week. InnoPharma’s portfolio includes 10 generic products approved by the United States Food and Drug Administration and has more than 30 injectable and ophthalmic treatments in development. The deal is expected to close during the third quarter.

“It is an important milestone as we continue to look for innovative growth opportunities for our sterile injectables portfolio,” says John Young, president of the Pfizer Global Established Pharma business.

WeBleed will bring you more information on this development as it becomes available.

Photo Credit – Pfizer 

webleed.org – your source for bleeding news!